Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Song‐Yang Wu"'
Autor:
Chao Chen, Cai-Jin Lin, Yu-Chen Pei, Ding Ma, Li Liao, Si-Yuan Li, Lei Fan, Gen-Hong Di, Song-Yang Wu, Xi-Yu Liu, Yun-Jin Wang, Qi Hong, Guo-Liang Zhang, Lin-Lin Xu, Bei-Bei Li, Wei Huang, Jin-Xiu Shi, Yi-Zhou Jiang, Xin Hu, Zhi-Ming Shao
Publikováno v:
Cell Discovery, Vol 9, Iss 1, Pp 1-22 (2023)
Abstract Germline-somatic mutation interactions are universal and associated with tumorigenesis, but their role in breast cancer, especially in non-Caucasians, remains poorly characterized. We performed large-scale prospective targeted sequencing of
Externí odkaz:
https://doaj.org/article/e84cc79299584a45a1cc58c8e60cfc41
Autor:
Lei-Jie Dai, Ding Ma, Yu-Zheng Xu, Ming Li, Yu-Wei Li, Yi Xiao, Xi Jin, Song-Yang Wu, Ya-Xin Zhao, Han Wang, Wen-Tao Yang, Yi-Zhou Jiang, Zhi-Ming Shao
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract The molecular heterogeneity and distinct features of HER2-low breast cancers, particularly in the Chinese population, are not well understood, limiting its precise management in the era of antibody‒drug conjugates. To address this issue, w
Externí odkaz:
https://doaj.org/article/d72be25aa7d044a0b0ff35656eb21e54
Autor:
Song-Yang Wu, Ying Xu, Li Chen, Lei Fan, Xiao-Yan Ma, Shen Zhao, Xiao-Qing Song, Xin Hu, Wen-Tao Yang, Wen-Jun Chai, Xiao-Mao Guo, Xi-Zi Chen, Yan-Hui Xu, Xiao-Yu Zhu, Jian-Jun Zou, Zhong-Hua Wang, Yi-Zhou Jiang, Zhi-Ming Shao
Publikováno v:
Molecular Cancer, Vol 21, Iss 1, Pp 1-15 (2022)
Abstract Background Immune checkpoint inhibitors had a great effect in triple-negative breast cancer (TNBC); however, they benefited only a subset of patients, underscoring the need to co-target alternative pathways and select optimal patients. Herei
Externí odkaz:
https://doaj.org/article/e0dbceec56ca46efaf601443a7bfe647
Publikováno v:
Cancer Communications, Vol 41, Iss 10, Pp 968-980 (2021)
Abstract Hormone receptor testing mainly serves the purpose of guiding treatment choices for breast cancer patients. Patients with estrogen receptor (ER)‐positive breast cancers show significant response to endocrine therapy. However, the methods t
Externí odkaz:
https://doaj.org/article/3b2ea1e1305e4654b01c5b440d7619b3
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-25 (2021)
Abstract Tumors are not only aggregates of malignant cells but also well-organized complex ecosystems. The immunological components within tumors, termed the tumor immune microenvironment (TIME), have long been shown to be strongly related to tumor d
Externí odkaz:
https://doaj.org/article/a7bef537608d4a798f2902a1bc079840
Publikováno v:
Molecular Cancer, Vol 19, Iss 1, Pp 1-26 (2020)
Abstract The tumor microenvironment is highly complex, and immune escape is currently considered an important hallmark of cancer, largely contributing to tumor progression and metastasis. Named for their capability of killing target cells autonomousl
Externí odkaz:
https://doaj.org/article/b53886b560604fe383564c8920420d85
Autor:
Yin Liu, Xiu-Zhi Zhu, Yi Xiao, Song-Yang Wu, Wen-Jia Zuo, Qiang Yu, A-Yong Cao, Jun-Jie Li, Ke-Da Yu, Guang-Yu Liu, Jiong Wu, Tao Sun, Jiu-Wei Cui, Zheng Lv, Hui-Ping Li, Xiao-Yu Zhu, Yi-Zhou Jiang, Zhong-Hua Wang, Zhi-Ming Shao
Publikováno v:
Cell Research. 33:389-402
Triple-negative breast cancer (TNBC) is a heterogeneous disease and lacks effective treatment. Our previous study classified TNBCs into four subtypes with putative therapeutic targets. Here, we report the final results of FUTURE, a phase II umbrella
Autor:
Zhi-Ming Shao, Zhong-Hua Wang, Yi-Zhou Jiang, Yin Liu, Xiu-Zhi Zhu, Yi Xiao, Song-Yang Wu, Wen-Jia Zuo, Qiang Yu, A-Yong Cao, Jun-Jie Li, Ke-Da Yu, Guang-Yu Liu, Jiong Wu, Tao Sun, Jiuwei Cui, Zheng Lv, Hui-Ping Li, Xiao-Yu Zhu
Publikováno v:
Cancer Research. 83:OT3-27
Background: Triple-negative breast cancer (TNBC) is a heterogeneous disease and lacks effective treatment. Our previous study classified TNBCs into four subtypes (luminal androgen receptor [LAR], immunomodulatory [IM], basal-like immune-suppressed [B
Autor:
Lei-Jie Dai, Ding Ma, Yi Xiao, Xi Jin, Song-Yang Wu, Ya-Xin Zhao, Han Wang, Wen-Tao Yang, Yi-Zhou Jiang, Zhi-Ming Shao
Publikováno v:
Cancer Research. 83:HER2-09
Background: The emergence of anti-HER2 antibody–drug conjugates (ADCs) gave rise to the concept of HER2-low breast cancer (BC). HER2-low BC, which refers to a subgroup of HER2-negative BC with relatively higher HER2 expression (defined as 1+ or 2+
Autor:
Song-Yang Wu, Si-Wei Zhang, Ding Ma, Yi Xiao, Yin Liu, Li Chen, Xiao-Qing Song, Xiao-Yan Ma, Ying Xu, Wen-Jun Chai, Xi Jin, Zhi-Ming Shao, Yi-Zhou Jiang
Publikováno v:
Med.